Antibiotic treatment duration and prevention of complications in neonatal Staphylococcus aureus bacteraemia

The Journal of Hospital Infection
S KempleyM Millar

Abstract

In adults with Staphylococcus aureus bacteraemia, short duration of effective antibiotic treatment is associated with increased risk of complications and recurrence. The optimum duration of treatment for neonates is unknown and practice varies widely. To relate the duration of treatment of neonatal S. aureus bacteraemia to prevention of complications and recurrence. Retrospective cohort study of confirmed S. aureus bacteraemia occurring over a 10 year period in two large tertiary neonatal units. Neonatal patients developing confirmed S. aureus bacteraemia between birth and discharge from the neonatal unit were identified from microbiology department records. Clinical details obtained from case notes included demographics, duration of antibiotics and clinical outcomes. Recurrence was determined from laboratory and clinical records. Adverse outcomes were related to duration of antibiotic therapy. A total of 90 infants had S. aureus bacteraemia, of which six were meticillin-resistant S. aureus (7%). Median gestation was 27 weeks (range: 23-41), birth weight 846 g (434-3840) and postnatal age 16 days (0-116). Adverse outcomes were found in 44%, with death in 8%. Median duration of appropriate antibiotics was 19 days (range: 0-54). ...Continue Reading

References

Feb 1, 1988·The Journal of Hospital Infection·A FleerJ Verhoef
Aug 10, 2000·British Journal of Haematology·R Carr
Jun 5, 2001·Pediatrics·D K BenjaminK A Alexander
Nov 8, 2005·Internal Medicine Journal·D H Mitchell, B P Howden
Mar 14, 2009·The Journal of Antimicrobial Chemotherapy·F Kate GouldUNKNOWN MRSA Working Party of the British Society for Antimicrobial Chemotherapy
Apr 25, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Ralph Corey
Jun 10, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·S C SlootA H van Kaam
Jun 30, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·B Muller-PebodyUNKNOWN iCAP Group (Improving Antibiotic Prescribing in Primary Care)
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Mar 5, 2011·The Lancet Infectious Diseases·Guy E ThwaitesUNKNOWN UK Clinical Infection Research Group
Mar 16, 2011·The Journal of Infection·Hilmir AsgeirssonOlafur Gudlaugsson
Nov 13, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Susan N HocevarFernanda C Lessa

❮ Previous
Next ❯

Citations

Dec 10, 2016·Acta Paediatrica·Martin DragesetClaus Klingenberg
Jun 6, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anita J CampbellAsha C Bowen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.